• Explore /
  • Poster
  • / Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors.

Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors.

Abstract Poster

Authors

null

Ye Guo

Oncology, Shanghai East Hospital, Tongji University, School of Medicine, Shanghai, China

Ye Guo , Baogang Liu , Dongqing Lv , Ying Cheng , Tong Zhou , Yahua Zhong , Changlu Hu , Gang Chen , Xiaohua Wu , Yongmei Yin , Lihua Wu , Zhendong Chen , Hong Luo , Xiaohong Zhou , Yanru Qin , Yuxing Yang , SuXia Luo , Yanjie Ma , Yalin Li , Guoqiang Hu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

ChiCTR2000033828

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2512)

DOI

10.1200/JCO.2022.40.16_suppl.2512

Abstract #

2512

Poster Bd #

168

Abstract Disclosures

Similar Posters

First Author: Jermaine Coward

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

First Author: Jing Huang

First Author: Francisco Robert

First Author: Stéphane Champiat